I interpreted the same...and I believe Evotec to be the most plausible entity. 8000 mg of li eardna was shipped to test it 2 yrs ago and I bet a very big part of it went to Evotec. This drugdiscovery co has many alliances with many big pharma players (from their site:
and has a big hand in gene and CART therapy as well.Tehy had a PR-ed partnership on gene therapy with Takeda since april 2020
I might be wrong and the big pharma player might be one of Evotecs partners (Evotec itself is no Top 20 pharmaplayer), but I think I am not where it concerns the impact the "solved lineardna production challenge" (closing the open ends) might have on future dna production.
Like Touchlight's doggybone dna adnas seems to have created a similar(?) solution. Gotta dig in other competitors and see how what they do and have accomplished. Touchlight (private) for instance just partnered with Cancer Research UK and University of Southhampton...and this seems to.indicate Adnas is in front as well.
Dont know if different ways of closing the open ends of lineardna exist (must be I think) and if so they also have different impacts or additional (dis)advantages.